Evommune, Inc.
New York Stock ExchangeTotal Valuation
Evommune, Inc. carries a market capitalization of 199.24M, placing it among publicly traded companies globally. Its enterprise value stands at 289.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 199.24M |
| Enterprise Value | 289.50M |
Share Statistics
Evommune, Inc. currently has 36.28M shares outstanding.
| Shares Outstanding | 36.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 39.76, and the price-to-book ratio stands at 1.74.
| PE Ratio | N/A |
| PS Ratio | 39.76 |
| PB Ratio | 1.74 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | -5.40 |
| P/OCF Ratio | -5.36 |
Enterprise Valuation
| EV / Sales | 28.95 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Evommune, Inc. maintains a current ratio of 11.68, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.68 |
| Quick Ratio | 11.48 |
| Debt / Equity | 2.92 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -68.21 |
| Return on Assets (ROA) | -62.71 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Evommune, Inc.'s stock has declined approximately -72.86209% over the past 52 weeks. The 50-day moving average sits at 10.33, while the 200-day moving average is 18.34.
| Beta (5Y) | N/A |
| 52-Week Price Change | -72.86209% |
| 50-Day Moving Average | 10.33 |
| 200-Day Moving Average | 18.34 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Evommune, Inc. generated 10.00M in revenue and converted that into -94.67M in net income, yielding earnings per share of -3.16. EBITDA reached -100.35M, while operating income came in at -101.89M.
| Revenue | 10.00M |
| Gross Profit | N/A |
| Operating Income | -101.89M |
| Pretax Income | -94.67M |
| Net Income | -94.67M |
| EBITDA | -100.35M |
| EBIT | -101.89M |
| Earnings Per Share (EPS) | -3.16 |
Balance Sheet
Evommune, Inc. holds 200.79M in cash and equivalents against 8.11M in total debt, resulting in a net debt position of -60.03M. Total book value stands at 277.59M, with working capital of 186.76M providing operational flexibility.
| Cash & Cash Equivalents | 200.79M |
| Total Debt | 8.11M |
| Net Debt | -60.03M |
| Equity (Book Value) | 277.59M |
| Book Value Per Share | 7.65 |
| Working Capital | 186.76M |
Cash Flow
Evommune, Inc. produced -74.15M in operating cash flow over the past twelve months. After subtracting -501,000.00 in capital expenditures, free cash flow totaled -74.65M - equivalent to -2.50 per share.
| Operating Cash Flow | -74.15M |
| Capital Expenditures | -501,000.00 |
| Free Cash Flow | -74.65M |
| FCF Per Share | -2.50 |
Margins
Evommune, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,018.93 and net profit margin of -946.68 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,018.93 |
| Pretax Margin | -946.68 |
| Profit Margin | -946.68 |
| EBITDA Margin | -1,003.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -56.87 |
| FCF Yield | -18.53 |
Scores
Evommune, Inc. posts an Altman Z-Score of 10.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.26 |